Seeking Alpha

Specialty pharmaceutical firm Eurand (EURX) agrees to be bought for $12/share in cash by Axcan...

Specialty pharmaceutical firm Eurand (EURX) agrees to be bought for $12/share in cash by Axcan holdings, a pharma firm focused on gastrointestinal disorders. The $583M deal is a 9% premium to Eurand's close yesterday. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)